What is the basis for Gerry Pharmaceuticals to enter the oncology market?

PART.
03

Continue to exert force

Strategic layout in the field of oncology

It can be understood from the official announcement of Gall that Gall's tumor pipeline includes two mechanisms of tumor lipid metabolism and oral checkpoint inhibitors, and four drugs
.
In addition to ASC40, which is about to launch a key phase II clinical study in China, it also includes a new generation of FASN inhibitor ASC60, and two self-developed oral PD-L1 small molecule inhibitors
.
At the beginning of its debut, Gallée's tumor pipeline has a strong competitive advantage in the highly competitive tumor field
.

Judging from the indications of Gerry's pipeline in the oncology field, the FASN series inhibitors are facing an out-and-out "blue ocean" market
.
The "Guidelines for the Diagnosis and Treatment of Glioma" (2018 Edition) disclosed that the annual incidence of glioma in China is about 5 to 8 per 100,000 people, but there is currently no standard for recurring glioma after standard treatment
.
In addition to brain gliomas, FASN inhibitors are also expected to be used in non-small cell lung cancer, rectal cancer, breast cancer, prostate cancer and other solid tumors that highly express FASN during tumor progression.
The application market has great expansion.
Space
.

Moreover, FASN inhibitors mainly intervene in the lipid metabolism pathway of tumors, and have the basis for joint use with the current mainstream anti-angiogenesis (Angiogenesis), tumor-targeted therapy, and immunotherapy
.
At present, many in vitro and animal experiments have shown that the combination of FASN inhibitors and other mechanisms can inhibit tumors more significantly than single drugs
.
The Phase II data of the combined use of ASC40 and BEV also provide valuable clinical support for this direction.
If the FASN inhibitor series can be successfully commercialized, it can be combined with existing anti-tumor drugs with different mechanisms to obtain a broader business The Red Sea is not popular in the space of transformation
.

In addition, strong R&D execution is also the core element of Gerry's deployment of innovative drug research and development in the oncology field
.
It took only 33 months for Gale to achieve the IND approval of a drug to the harvest of the new drug certificate
.
Chairman Dr.
Wu Jinzi and CSO Dr.
Hanhan He have been deeply involved in the oncology field for many years, and they have the strategic vision and ability to lead R&D teams in the oncology market
.
We look forward to Geli's continued efforts to advance FASN and even lipid metabolism pathway research to the commercialization stage as soon as possible, benefiting cancer patients
.

Reference material: Gallite Pharmaceutical's official website